Table 2.
Study and patient characteristics
| Characteristic | Result |
|---|---|
| Patient RCTs, n (%) | 94 (66.2) |
| Cluster RCTs, n (%) | 48 (33.8) |
| Number of clusters, median (IQR) | 29 (12, 57) |
| Number of patients, median (IQR) | 405.3 (203, 878) |
| Duration of intervention months, median (IQR) | 12 (8.9, 15.0) |
| Mean age in years, median (IQR) | 59.4 (54.9, 62.9) |
| Percentage of male, median (IQR) | 49.8 (41.8, 55.9) |
| Type of diabetes n (%) | |
| Type 1 diabetes | 9 (6.3) |
| Type 2 diabetes | 80 (56.3) |
| Type 1 and 2 diabetes | 34 (23.9) |
| Type of diabetes unclear/NR | 19 (13.4) |
| Number of QIs per RCT median (IQR) | 2 (0, 3.5) |
| Administrators of patient intervention(s), n (%) | |
| Primary care physician | 30 (21.1) |
| Nurse | 67 (47.2) |
| Pharmacist | 19 (13.4) |
| Dietician | 22 (15.5) |
| Psychiatrist | 3 (2.1) |
| Psychologist | 2 (1.4) |
| Ophthalmologist | 2 (1.4) |
| Specialist/endocrinologist | 21 (14.8) |
| Other | 49 (34.5) |
| Location of study, n (%) | |
| The USA | 68 (47.9) |
| The UK | 14 (9.9) |
| Canada | 11 (7.7) |
| The Netherlands | 8 (5.6) |
| South Korea | 7 (4.9) |
| Australia | 6 (4.2) |
| Denmark | 3 (2.1) |
| Belgium | 1 (0.7) |
| Israel | 3 (2.1) |
| Spain | 3 (2.1) |
| Norway | 2 (1.4) |
| France | 2 (1.4) |
| Germany | 2 (1.4) |
| Italy | 2 (1.4) |
| Switzerland | 2 (1.4) |
| China | 2 (1.4) |
| Ireland | 1 (0.7) |
| New Zealand | 1 (0.7) |
| Thailand | 1 (0.7) |
| Taiwan | 1 (0.7) |
| United Arab Emirates | 1 (0.7) |
| Mexico | 1 (0.7) |
All IQRs reported as the 25th and 75th percentiles, includes investigators and community workers.
N, number; NA, not applicable; NR, not reported; QI, quality improvement; RCT, randomised clinical trial.